HGS Submits BLA For Interferon Zalbin For Hepatitis C
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved, the interferon could offer a dosing advantage over pegylated interferons, although safety data could mean a bumpy regulatory road ahead.
You may also be interested in...
Novartis And HGS Close The Door On Zalbin
Development of hepatitis C drug concluded after FDA "complete response" letter and disappointing monthly dosing data.
Novartis And HGS Close The Door On Zalbin
Development of hepatitis C drug concluded after FDA "complete response" letter and disappointing monthly dosing data.
Merck And Vertex Poised For Growth In Singapore's HCV Market As Medical Tourism Booms
SHANGHAI - Novel hepatitis C treatments from Merck and Vertex are expected to fare well in Singapore - with the proper marketing campaigns - due in part to increased medical tourism from neighboring Southeast Asian countries